Abstract: The invention relates to compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are identical or different and are hydrogen, alkyl, trifluoromethyl, halogen, alkoxycarbonyl, alkoxy or alkanoyl, R.sup.3, R.sup.4 and R.sup.5 are identical or different and are hydrogen, methyl, alkoxy or alkoxyethoxy, and R is hydrogen or a group SR.sup.6, in which R.sup.6 is the lone, unpaired electron of the 12-sulfenyl radical, hydrogen, optionally substituted alkyl, alkenyl, alkynyl, alkanoyl, optionally mono- or poly-substituted benzoyl, fuoryl, phenacyl, phenoxyacetyl, phenylacetyl or another conventional thiol-protective group, and to physiologically acceptable salts thereof, and to processes for their preparation, to their use as a gastric acid secretion inhibitor and to pharmaceutical preparations based on these compounds.

Abstract: Salicylic acid derivatives of the formula I ##STR1## wherein R.sup.1, W, X, Y and Z have the meanings indicated or a physiologically tolerated salt thereof, processes for their preparation, pharmaceutical formulations based on these compounds and their use as antidiabetic agents.

Abstract: Sulfonylureas of the formula ##STR1## in which Y denotes alkylene having 2-3 C atoms, R denotes alkyl having 1-4 C atoms, R.sup.1 denotes hydrogen, chlorine or methyl, and R.sup.2 denotes alkyl having 3-6 C atoms, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkenyl, alkylcycloalkenyl or cycloalkenylalkyl, each having 5-8 C atoms, and their physiologically tolerated salts, and processes for their preparation and medicaments prepared therefrom.

Abstract: What are disclosed are sulfonyl ureas of the formula ##STR1## in which R.sup.1, X and Y are as defined in the specification, and their physiologically acceptable salts, pharmaceutical formulations on the basis of these compounds, and their use in the treatment of diabetes.

Abstract: Sulfonylureas of the formula ##STR1## in which ##STR2## R.sup.1, X and Y have the indicated meanings and the physiologically acceptable salts thereof, pharmaceutical preparations on the basis of said compounds and their use in the treatment of diabetes.

Abstract: Sulfonylureas of the formula ##STR1## wherein R.sup.1, X and Y have the indicated meanings, as well as their physiologically acceptable salts, pharmaceutical preparations on the basis of these compounds and their use in the treatment of diabetes.

Abstract: Sulfonylureas of the formula ##STR1## wherein n, R, R.sup.1 and X have the indicated meanings, as well as their physiologically acceptable salts, pharmaceutical preparations on the basis of these compounds and their use for treating diabetes.

Abstract: Sulfonylureas of the formula ##STR1## in which n, R, R.sup.1, X and Y have the indicated meanings and the physiologically acceptable salts thereof, pharmaceutical preparations on the basis of said compounds and their use in the treatment of diabetes.

Abstract: Phenylacetic acid derivatives of the formula ##STR1## wherein A is an aryl radical optionally substituted by halogen, trifluoromethyl, alkyl, alkoxy, alkenyloxy, alkoxyalkoxy, alkyl-substituted amino or aryloxy, or a heterocyclic ring system optionally substituted by halogen, alkyl or alkoxy,Y is a valency bond or an optionally branched alkylene radical containing up to 3 carbon atoms, andR.sub.1 and R.sub.2 each independently is hydrogen or a lower alkyl radical,or a physiologically compatible salt or ester thereof, exhibit marked hypoglycaemic and hypolipidaemic activity.

Abstract: Acyl-aminoalkyl-benzoic acid and derivates thereof show a blood sugar lowering effect upon oral administration and can be used as orally applicable hypoglycemiants.

Abstract: Phenylacetic acid derivatives of the formula ##STR1## wherein A is an aryl radical optionally substituted by halogen, trifluoromethyl, alkyl, alkoxy, alkenyloxy, alkoxyalkoxy, alkyl-substituted amino or aryloxy, or a heterocyclic ring system optionally substituted by halogen, alkyl or alkoxy,Y is a valency bond or an optionally branched alkylene radical containing up to 3 carbon atoms, andR.sub.1 and R.sub.2 each independently is hydrogen or a lower alkyl radical,or a physiologically compatible salt or ester thereof, exhibit marked hypoglycaemic and hypolipidaemic activity.

Abstract: Benzoic acids of the general formula I ##STR1## in which R, R.sup.1, R.sup.2 and Y have the meanings as mentioned in the following, and which in the form of the free compounds or in the form of the physiologically tolerated salts and esters possess valuable pharmacological properties, processes for preparing them, pharmaceutical preparations containing them, and their use as or in medicaments.

Abstract: Benzoic acid derivatives of the formula ##STR1## wherein T is hydrogen or halogen, W is a carboxyl group, an ester or salt thereof; X is ##STR2## wherein R.sub.1 is alkyl having from 2 to 8 carbon atoms, aralkyl or phenyl, cycloalkyl, cycloalkylalkyl or alkylcycloalkyl; R.sub.2 is hydrogen or halogen, R.sub.3 is alkyl having from 5 to 8 carbon atoms, aralkyl or phenyl, or cycloalkyl having from 5 to 8 carbon atoms; R.sub.4 is hydrogen or alkyl; Y is a single chemical bond or a hydrocarbon chain having from 1 to 3 carbon atoms; and Z is hydrogen, halogen, alkyl, alkoxy, alkoxyalkoxy or alkenyloxy, have a blood sugar lowering effect and can be used for the treatment of Diabetes mellitus.

Abstract: The invention relates to acylamino(alkyl)benzene derivatives of the general formula ##STR1## in which W represents a group which can be converted into a carboxyl group, or an aldehyde group or an oxymethyl group or their derivatives or also a low molecular weight alkyl group, preferably a methyl group,X represents an aromatic or hetero-aromatic ring system,Y represents a single chemical bond or a hydrocarbon bridge, andZ represents hydrogen or one or even several other substituents,To their preparation and to pharmaceutical compositions containing them. The compounds have blood sugar lowering activity and may be used in the therapy of diabetes mellitus.

Abstract: Benzenesulfonyl ureas of the formula ##STR1## in which R, R.sup.1, X, X.sup.1 and Y have the defined meanings, and the salts thereof, process for preparing these compounds, pharmaceutical preparations containing them and their use for lowering the blood sugar level.

Abstract: Benzenesulfonyl ureas of the formula ##STR1## in which R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and Y have the defined meanings, and the salts thereof, process for preparing them, pharmaceutical preparations containing them and their use for lowering the blood sugar level.

Abstract: Sulfonyl-ureas of the formula ##STR1## wherein X represents a heteroaromatic 5- or 6-ring substituted, if desired, by one or two methyl groups and/or annellated with benzene, which ring may contain in addition to a nitrogen atom a further nitrogen, oxygen or sulfur atom and which, in vicinal position to the nitrogen atom, is linked to the rest of the molecule portion, R is alkyl having 1 to 3 carbon atoms, R.sup.1 is alkyl having 3 to 6 carbon atoms, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkenyl, alkylcycloalkenyl having each 5 to 9 carbon atoms, cyclohexenylmethyl, chlorocyclohexyl, bicycloheptenylmethyl, bicycloheptylmethyl, bicycloheptenyl, bicycloheptyl, nortricyclyl, adamantyl, benzyl, which as substance or in form of the salts thereof have hypoglycemic properties and are distinguished by a strong and continuous lowering of the blood sugar level, process for preparing them as well as pharmaceutical preparations containing the sulfonyl-ureas as an active substance.

Abstract: N-acylaminoalkyl-benzenesulfonyl-N'-methyl ureas, especially those of the general formula ##STR1## in which R is C.sub.1-- C.sub.4 --alkyl or a phenyl radical substituted in 2-position by alkoxy of 1 to 4 carbon atoms, phenoxy or dimethylamino and in 5-position by H, CH.sub.3, Cl or Br, their manufacture and their use as oral antidiabetics.

Abstract: Sulfonyl-ureas of the formula X--CO--NH--A--SO.sub.2 --NH--CO--NH--R.sup.1, in which R.sup.1 represents cyclopentylmethyl, alkyl-cyclopentylmethyl or dialkyl-cyclopentylmethyl, having up to 2 carbon atoms in the alkyl rest, or cyclopentylethyl, X represents a. ##SPC1##In which R.sup.2 represents hydrogen, F, Cl, Br, CF.sub.3, CH.sub.3 or OCH.sub.3,b. ##SPC2##In which R.sup.3 represents hydrogen, Cl or CH.sub.3,c. ##SPC3##In which R.sup.4 represents hydrogen, Cl or Br,A represents one of the groupings ##SPC4##And their physiologically tolerated salts, process for preparing them and pharmaceutical preparations containing them.

Abstract: Benzene sulfonyl ureas of the formula ##SPC1##In whichR represents a hydrogen, chlorine, or bromine atom, a methoxy or methyl group,--X--Y-- represents --N=CH--, --NH--CH.sub.2 --, --NH--CO--, ##EQU1## the alkyl herein containing from 1 to 4 carbon atoms, R.sup.2 represents an alkyl group having 1 to 4 carbon atomsR.sup.1 represents an alkyl group having from 3 to 6 carbon atoms, a cycloalkyl group having from 5 to 8 carbon atoms, 3-ethyl-cyclopentyl, methyl-cyclopentyl, dimethylcyclopentyl, 4-alkyl-cyclohexyl having from 1 to 3 carbon atoms in the alkyl group, cyclopentenyl, cyclohexenyl, cycloheptenyl, 4-chloro-cyclohexyl, 4,4-dimethylcyclohexyl, 3-methyl-cyclopentenyl, 4-methylcyclohexenyl, endoalkylene-cyclohexyl, endoalkylene-cyclohexenyl, bicyclo-(2.2.1) hept-2-en-7-yl, and their physiologically tolerable salts, useful for lowering blood sugar level in the treatment of diabetes mellitus.